Abstract: The present invention is related to the manufacturing of mRNA for use in immunotherapy or for use in immunotherapy screening. Compared to existing methods the present approach is plasmid-free, fast and inexpensive, allowing screening of potential neoantigen in immunotherapy.

Abstract: The invention is situated in the field of cancer immunotherapy and more specifically the maturation of antigen-presenting cells in order to enhance their potency to induce an immune response.

Abstract: According to some embodiments, an emission tomography scanner may acquire emission scan data. One or more anatomical images may be generated using an anatomical imaging system, and the anatomical images may be processed to obtain an initial attenuation image. An emission image and a corrected attenuation image may be jointly reconstructed from the acquired emission scan data, the corrected attenuation image representing a deformation of the initial attenuation image. A final reconstructed emission image may then be calculated based on the reconstructed emission image and/or the corrected attenuation image. The final reconstructed emission image may then be stored in a data storage system and/or displayed on a display system.

Abstract: According to some embodiments, an emission tomography scanner may acquire emission scan data. One or more anatomical images may be generated using an anatomical imaging system, and the anatomical images may be processed to obtain an initial attenuation image. An emission image and a corrected attenuation image may be jointly reconstructed from the acquired emission scan data, the corrected attenuation image representing a deformation of the initial attenuation image. A final reconstructed emission image may then be calculated based on the reconstructed emission image and/or the corrected attenuation image. The final reconstructed emission image may then be stored in a data storage system and/or displayed on a display system.

Abstract: The present invention relates to a method of producing a plurality of dendritic cell/tumor cell hybrids which induce an anti-tumor response when applied to a patient. The present invention further relates to a method of producing a dendritic cell/tumor cell hybridoma which induces an anti-tumor response when applied to a patient.

Abstract: Peptides which consist of amino acid sequences found in MAGEA3 bind to HLA-Cw*07 molecules to form T cell epitopes. The therapeutic and diagnostic ramifications of this are the subject of this invention, as are various products obtained in the course of the development of the invention.

Abstract: The invention describes HLA class II binding peptides encoded by the MAGE-3 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4+ T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the MAGE-3 gene.

Abstract: Detector efficiency data is generated for a positron emission tomography scanner (2) including a single photon source by conducting a blank scan acquisition procedure using the single photon source. The acquired detection count data is processed using an efficiency estimation algorithm to calculate data efficiencies of individual detectors in the detector array (8). In one embodiment, the detection count data is output as artificial coincidence count data and the efficiency estimation algorithm operates on the artificial coincidence count data. The method can be used in a non-rotating scanner or a rotating scanner.

Abstract: Peptides which consist of amino acid sequences found in MAGEA3 bind to HLA-Cw*07 molecules to form T cell epitopes. The therapeutic and diagnostic ramifications of this are the subject of this invention, as are various products obtained in the course of the development of the invention.

Abstract: The invention describes HLA class II binding peptides encoded by the MAGE-A3 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4+ T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the MAGE-A3 gene.

Abstract: The invention describes HLA class II binding peptides encoded by the MAGE-3 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4+T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the MAGE-3 gene.

Abstract: The present invention is related to hybrids and hybridomas consisting of a fused tumor cell and a dendritic cell, which is capable of inducing an anti-tumor response in vivo when administered to a subject in need of anti-tumor treatment. A method of activating autologous immune cells in vitro is disclosed, wherein the method comprises co-cultivating a dendritic cell/tumor cell hybridoma or a plurality of dendritic cell/tumor cell hybrids with immune cells from a mammalian subject.

Abstract: The present invention relates to a method of producing a plurality of dendritic cell/tumor cell hybrids which induce an anti-tumor response when applied to a patient. The present invention further relates to a method of producing a dendritic cell/tumor cell hybridoma which induces an anti-tumor response when applied to a patient.

Abstract: The present invention is related to a plurality of dendritic-like cell/tumor cell hybrids which is capable of inducing an anti-tumor response.

Abstract: The invention describes HLA class II binding peptides encoded by the MAGE-3 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4+ T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the MAGE-3 gene.

Abstract: The invention describes HLA class II binding peptides encoded by the MAGE-3 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4+ T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the MAGE-3 gene.